IgA nephropathy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BCMA 7
• CD19 8
• SGLT2 1
• CD20 0
• CD38 0
• IL-6 0
• JAK 0
• NLRP3 0
• TLR4 0
• mTOR 0
• STING 0
• IL-17 0
• AKT 0
• AMPK 0
• EGFR 0
• FAK 0
• GPX4 0
• HER2 0
• IL-1 0
• MET 0
• MYC 0
• NRF2 0
• PD-1 0
• PI3K 0
• STAT3 0
• TP53 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDDK · R01

  Determination of structural features critical for nephritogenic properties of IgA1-containing immune complexes in IgA nephropathy

  University of Alabama at Birmingham· Birmingham, United States· US$743,278 awarded in fiscal year 2026· until May 2030

• NIH NIDDK · R01

  Dapagliflozin in Active Lupus Nephritis: A Pilot and Feasibility Randomized Trial

  Brigham and Women's Hospital· Boston, United States· US$364,560 awarded in fiscal year 2026· until Dec 2028

• NIH NIDDK · F32

  The Impact of APOL1 Copy Number Variation on Kidney Disease Susceptibility in African Americans

  Beth Israel Deaconess Medical Center· Boston, United States· US$79,348 awarded in fiscal year 2026· until Aug 2027

• NIH NIDDK · R01

  Interrogating The Biology Of Human Lupus Nephritis Using Single Cell Resolution Spatial Transcriptomics

  Seattle Children's Hospital· Seattle, United States· US$801,241 awarded in fiscal year 2026· until Jan 2028

• NIH NIAID · R01

  Contributions of autophagy-related genes in lupus

  Oklahoma Medical Research Foundation· Oklahoma City, United States· US$751,755 awarded in fiscal year 2026· until Jul 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Role of CD1c-reactive T cells and lipid antigens in post-streptococcal disease (CReativeLipid)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €1,491,316· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Antigen-specific treatments to target autoimmune kidney diseases (AUTO-TARGET)

  Universitaetsklinikum Hamburg-Eppendorf· Hamburg, Germany· EU contribution €1,499,663· until Mar 2030

• European Commission (Horizon Europe) · HORIZON-RIA

  Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology (geneTIGA)

  Charite - Universitaetsmedizin Berlin· Berlin, Germany· EU contribution €6,393,734· until Dec 2026· 8 countries

8 of 22 running projects, newest first. Listed amounts together: US$11.1m + €9.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 14
• Gene Expression Profiling 14
• Proteomics 8
• Metabolomics 5
• Flow Cytometry 2
• Immunohistochemistry 4
• Magnetic Resonance Imaging 1
• Machine Learning 9
• Deep Learning 3
• Cohort Studies 14
• Genome-Wide Association Study 20

• Targeted-Release Budesonide in Chinese Patients with IgA Nephropathy: A Real-World Retrospective Cohort Study.

  Drug Des Devel Ther, Oct 2026

• Long-Term Autoimmune Risk Following Pediatric Acute Pyelonephritis: A Nationwide Cohort Study.

  Pathogens, Oct 2026

• Comparative Analysis of Clinical and Pathological Traits in IgA Nephropathy Patients with Nephrotic Syndrome or Nephrotic Range Proteinuria.

  Kidney Blood Press Res, Sept 2026

• A First-in-Japanese Phase 1, Double-Blind, Placebo-Controlled, Parallel-Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants.

  Clin Pharmacol Drug Dev, Sept 2026

• Impact of recurrent IgA nephropathy on long-term kidney transplant outcomes: a cohort comparison with autosomal dominant polycystic kidney disease.

  BMC Nephrol, Aug 2026

• IgA nephropathy occurrence, treatment, and prognosis in the last two decades in Denmark.

  Nephrol Dial Transplant, Jul 2026

• Incidence and risk factors for recurrent IgA nephropathy after kidney transplantation: A multicenter cohort study from Denmark.

  PLoS One, Jul 2026

• Physician Variability in Time to Kidney Biopsy and Glucocorticoid Prescription in IgA Nephropathy: A Population-Based Cohort Study.

  Kidney360, May 2026

• Landscape of kidney biopsy diagnoses in a Romanian pediatric cohort.

  BMC Nephrol, Apr 2026

• A nine-gene diagnostic model for IgA nephropathy based on multi-cohort machine learning: integrating gene expression and immunohistochemical validation.

  Ren Fail, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.